Skip to content
mapperlab
← Dashboard
Stock

TNYA

TENAYA THERAPEUTICS, INC.
Latest close $0.784 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
4
27 funds tracked
Ever held
7
Current + past
New this quarter
0
Exited this quarter
2

Marquee-fund ownership over time

Aug 9, 2024Feb 13, 2025Aug 14, 2025May 15, 2026
Now
4

This quarter's activity

New positions opened

None.

Positions exited

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Renaissance Technologies re-entered$2.65$0.78-70%
Citadel Advisors re-entered$2.83$0.78-72%
Two Sigma Investments$2.83$0.78-72%
Millennium Management$2.83$0.78-72%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
AQR Capital Management 2× in & out→ $0.86+96%
Point72 Asset Management→ $0.86+36%
D.E. Shaw→ $1.20-41%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Tenaya Therapeutics, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
10
Filings · last 90d
10
Total on file
119
Recent SEC buffer
Most recent
May 29, 2026

30d / 90d windows measured from May 29, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 119 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · TENAYA THERAPEUTICS, INC.

Annual figures sourced directly from TENAYA THERAPEUTICS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Net income
-$90.6M
FY2025+18% YoY
EPS (diluted)
$-0.5900
FY2025+55% YoY
Free cash flow(?)
-$68.88M
FY2025+25% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Tenaya Therapeutics, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Citadel AdvisorsQ1 2026open$0.63$0.78+24%
Point72 Asset ManagementQ1 2026Q2 2026$0.63$0.86+36%
Citadel AdvisorsQ3 2025Q4 2025$0.95$1.33+40%
AQR Capital ManagementQ2 2025Q2 2026$0.44$0.86+96%
Renaissance TechnologiesQ2 2025open$0.39$0.78+102%
D.E. ShawQ4 2024Q1 2025$2.02$1.20-41%
Citadel AdvisorsQ3 2024Q2 2025$2.83$0.44-85%
Two Sigma InvestmentsQ3 2024open$2.83$0.78-72%
AQR Capital ManagementQ3 2024Q4 2024$2.83$2.02-29%
Millennium ManagementQ3 2024open$2.83$0.78-72%
Renaissance TechnologiesQ3 2024Q1 2025$2.65$0.95-64%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.